The macroscopic and microscopical top features of these isolates were indistinguishable from those of E. Pasteuriana. The histologic results are proven in Fig. S3 in the Supplementary Appendix. Susceptibility to Antifungal Agents Minimum amount inhibitory concentrations were determined for 6 isolates and the type strain . The ideals had been higher for the echinocandins and flucytosine than for the triazoles and amphotericin B., and Fig. S4 in the Supplementary Appendix). The isolate of one patient was not available for sequencing. E. Pasteuriana was the closest genetic and morphologic relative to this new cluster. Pasteuriana. The an infection was fatal in three individuals. The chest radiographic findings mimicked those associated with tuberculosis in the majority of cases , and skin damage were considered to be suggestive of a disseminated fungal infection by the original attending doctors in mere a minority of cases.The PROPEL trial has been conducted under an agreement reached with the FDA under its Special Protocol Assessment process. The SPA process permits FDA evaluation of a clinical trial protocol designed to form the principal basis of an efficacy claim in support of a NDA, and provides an contract that the trial style, including trial size, clinical endpoints and/or data analyses are appropriate to the FDA. The response price, duration of response and security profile necessary to support FDA acceptance are not specified in the PROPEL trial protocol and will be at the mercy of FDA review. The FDA granted orphan medication designation and fast monitor designation to pralatrexate for the treating patients with T-cell lymphoma in July 2006 and September 2006, respectively.